Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 8—August 2019
Dispatch

Case Series Study of Melioidosis, Colombia

José Y. RodríguezComments to Author , Soraya E. Morales-López, Gerson J. Rodríguez, Carlos A. Álvarez-Moreno, Kelin Esquea, Heidy Pinzon, Luis R. Ramirez, Lilian Moreno, Walter Ocampo, and Martha L. Cepeda
Author affiliations: Hospital Rosario Pumarejo de López, Valledupar, Colombia (J.Y. Rodríguez); Centro de Investigaciones Microbiológicas del Cesar (CIMCE), Valledupar (J.Y. Rodríguez, G.J. Rodríguez); Clínica Laura Daniela, Valledupar (J.Y. Rodríguez, K. Esquea); Clínica Médicos LTDA, Valledupar (J.Y. Rodríguez, H. Pinzon); Laboratorios Nancy Flórez García S.A.S., Valledupar (S.E. Moralez-López); Universidad Popular del Cesar, Valledupar (S.E. Moralez-López); Universidad Nacional de Colombia, Bogotá, Colombia (C.A. Álvarez-Moreno); Clínica Universitaria Colombia, Clínicas Colsanitas, Bogotá (C.A. Álvarez-Moreno); Grupo de Investigaciones Microbiológicas del Cesar, Valledupar (L.R. Ramirez, L. Moreno); Corporación CorpoGen, Bogotá (W. Ocampo, M.L. Cepeda)

Main Article

Table 1

Epidemiologic and demographic characteristics, underlying conditions, clinical manifestations and outcomes of patients with melioidosis in the Caribbean coast region of Colombia*

Patient no. Patient age, y/ sex Medical history and risk factors Clinical manifestation Type of sample Empirical treatment Appropriate treatment (duration) ICU Outcome Relapse
1
 72/M
 Diabetes, arterial hypertension
 Bacteremic pneumonia
 Blood culture, urine culture, endotracheal aspirate
 TZP + CLR
 IP: MER + TMP/SMX (14 d); EP: NA
 Yes
 Died
 NA
2
 60/F
 Diabetes, arterial hypertension,
minor head injury with open scalp wound
 Bacteremic SSTI
 Wound secretion, blood culture
 CFZ + CLI
 IP: MER (10 d); EP: TMP/SMX (3 mo)
 No
 Alive
 No
3
 49/M
 Diabetes, leprosy, erythema nodosum leprosum, chronic use of steroids
 Bacteremic pneumonia
 Blood culture, urine culture, sputum culture
 TZP + CLR
 IP: MER (10 d); EP: TMP/SMX (6 mo)
 No
 Alive
 No
4
 71/M
 Arterial hypertension, multiple myeloma, bone marrow transplant, chronic use of steroids and thalidomide
 Bacteremic pneumonia
 Blood culture
 TZP + DOX
 IP: MER (14 d); EP: TMP/SMX (3 mo)
 No
 Alive
 No
5
 66/M
 Diabetes,
arterial hypertension
 Bacteremic pneumonia
 Blood culture, endotracheal aspirate
 TZP
 NA
 Yes
 Died
 NA
6
 56/M
 Diabetes, chronic renal failure
 UTI
 Urine culture
 TZP
 IP: MER (10 d); EP: TMP/SMX (3 mo)
 No
 Alive
 At 6 mo: bacteremia, UTI, SSTI
7 54/M Tibia and fibula open fracture SSTI Wound secretion, blood culture CFZ + CLI IP: MER (10 d); EP: TMP/SMX (6 mo) No Alive No

*CFZ, cefazolin; CLI, clindamycin; CLR, clarithromycin; DOX, doxycycline; EP, eradication phase; IP, intensive phase; MER, meropenem; NA, not available; SSTI, skin and soft tissue infection; TMP/SMX, trimethoprim/sulfamethoxazole; TZP, piperacillin/tazobactam; UTI, urinary tract infection.

Main Article

Page created: July 16, 2019
Page updated: July 16, 2019
Page reviewed: July 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external